marrow by the angiosarcoma is exceedingly uncommon and almost invariably found in patients with disseminated disease, usually with concomitant involvement of the spleen. To our knowledge, there have only been a few cases with bone marrow infiltration reported in the literature to date [3] [4] [5] [6] .
Clinical manifestations of bone marrow involvement by the angiosarcoma are nonspecific and include fatigue, weight loss, mucocutaneous bleeding and fever. Common laboratory findings are anemia and thrombocytopenia, which can be found in many patients. A leukoerythroblastic blood picture is also commonly observed [7] . A definitive diagnosis is difficult to make from cytologic material because of the technical difficulty in marrow aspiration and the paucity of diagnostic cells, probably due to an associated bone marrow fibrosis [8] . Therefore, the diagnosis relies on bone marrow trephine biopsy findings confirmed by the immunohistochemical profile. In general, the prognosis of metastatic angiosarcoma is very poor, with a median overall survival of less than 12 months [9, 10] . The mainstay treatment of metastatic angiosarcoma is not well defined. There are no randomized trials, and most published reports are based on retrospective case series [9, 10] with response rates varying between 16 and 36% [11] . Systemic single-agent chemotherapy has been the most common treatment approach, although the evidence base for this approach is limited. Anthracycline-based regimens and weekly paclitaxel remain the most commonly used first-line treatments in the metastatic setting [12] . Weekly paclitaxel has been shown to be an active agent in metastatic angiosarcomas [11] , and its benefit appears to be more pronounced in primary angiosarcomas arising in the scalp or breast [2] . Here, we describe the case of an angiosarcoma metastatic to the spleen and bone marrow, an extremely unusual presentation that challenges the primary diagnosis. Written informed consent was obtained from the patient's daughter for publication of this case report and any accompanying images.
Case Presentation
A 71-year-old woman was referred to the Hematology Clinic after a routine evaluation in which a complete blood count revealed anemia and thrombocytopenia. The patient noticed a cumulative weight loss of 12 kg in the previous year and progressive fatigue during the last 2 months. She denied fever, dyspnea, repeated infections or abdominal pain. There was a history of a gastric neuroendocrine tumor 2 years ago, which was surgically removed. The patient admitted that she had not had a gynecological follow-up for years. A physical examination revealed pallor, an exclusive left lobe hepatomegaly and massive splenomegaly with no palpable lymph node. The breast examination was normal. She had a poor performance status of 2. The peripheral blood counts revealed a hemoglobin level of 74 g/l (mean corpuscular volume 95 fl), platelet levels of 53 × 10 9 /l and a white blood cell count of 7.7 × 10 9 /l with a 4.9 absolute neutrophil count.
A bone marrow aspiration was dry tap. An imprint from the bone marrow biopsy was performed and showed moderate megaloblastic changes with a few groups of cohesive nonhematopoietic mononuclear cells with round to indented nuclei, homogeneously condensed chromatin, distinct nucleoli and deeply basophilic cytoplasm ( fig. 1 ). The bone marrow trephine biopsy revealed replacement of the normal hematopoietic elements by interstitial infiltration of malignant epithelioid cells with abundant eosinophilic cytoplasm, focal spindle-shaped cells lining cleft-like spaces and anastomosing vascular channels ( fig.  2 ). An immunohistochemical analysis revealed that tumor cells expressed the endothelial markers CD31, factor VIII ( fig. 3 ) and CD34 with no expression of epithelial markers, such as cytokeratin. HHV-8 was negative. The morphological and immunohistochemical findings were indicative of bone marrow infiltration by angiosarcoma.
The patient was referred to the Oncology Clinic for evaluation. Further workup was performed to identify other sites of involvement. Electrolytes, creatinine, lactate dehydrogenase and liver tests were within normal limits. The cancer antigen (CA) 15.3 level was slightly elevated (30 μg/l, normal <25 μg/l). The carcinoembryonic antigen, CA 19.9 and CA 125 levels were in the normal range. The patient underwent CT scans of the chest, abdomen and pelvis, which showed homogeneous enlargement of the liver and spleen. Bone scintigraphy was normal. A transvaginal ultrasound revealed an enlarged right ovary measuring 4.4 cm in the greatest diameter with a multisepted lesion. Upper gastrointestinal endoscopy and colonoscopy were performed, both with normal findings. With these results, we presumed the presence of a primary ovarian angiosarcoma with simultaneous involvement of the spleen, bone marrow and liver. Although the ovarian tumor was not biopsied, its radiological appearance together with the assumption that metastatic sarcoma is very rare in the ovary directed us to assume that the ovarian tumor was the primary site. In addition, no other plausible primary tumor was found in the workup. Systemic chemotherapy was recommended, and the patient began monotherapy with paclitaxel (80 mg/m 2 , intravenously, weekly on days 1, 8, 15 every 28 days). After 2 cycles, the patient developed a grade 3 peripheral neuropathy, and the treatment was halted. At that time, new CT scans showed a stable disease with a slight improvement in hemoglobin levels. The treatment was modified, and the patient underwent chemotherapy with pegylated liposomal doxorubicin (35 mg/m 2 , on day 1, intravenously, every 3 weeks). At the end of 6 cycles, there was a strong improvement in the hemoglobin levels to 119 g/l and a normalization of the platelet counts. A PET-CT was performed and revealed a complete reduction of the splenomegaly but no improvement in the hepatomegaly. In addition, a highly active metabolic lesion was still present in the right ovary. The bone marrow biopsy was repeated and showed a persistence of angiosarcoma cells. The patient showed an asymptomatic partial response with moderate treatment toxicity; therefore, it was decided to maintain the clinical follow-up until symptomatic progression. Seven months later, the patient started experiencing bone pain, and a new bone scintigraphy revealed diffuse osteoblastic lesions. The chest and abdominal CTs were repeated showing a 0.8-cm lung nodule as well as multiple liver metastases. Chemotherapy with gemcitabine (1,000 mg/m 2 , intravenously, on days 1, 8 and 15 every 28 days) plus zoledronic acid was initiated with no improvement after 2 cycles, and there was a significant decrease in the performance status. The patient died 5 months after palliative care initiation, 22 months after the diagnosis had been established.
Conclusions
Angiosarcomas can metastasize to the bone marrow, leading to a clinical picture that eventually mimics other more common bone marrow-replacing diseases, such as acute leukemia and non-Hodgkin lymphoma. In this sense, a high index of suspicion is necessary due to its rarity. Oncologists and hematologists need to be aware of this challenging diagnosis and to consider bone marrow evaluation, including cytology smear, in patients with angiosarcoma and peripheral blood count abnormalities. 
